PMC:7243778 / 25925-26779 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"639","span":{"begin":777,"end":778},"obj":"Gene"},{"id":"640","span":{"begin":350,"end":351},"obj":"Gene"},{"id":"641","span":{"begin":46,"end":54},"obj":"Species"},{"id":"642","span":{"begin":59,"end":67},"obj":"Species"},{"id":"643","span":{"begin":192,"end":200},"obj":"Species"},{"id":"644","span":{"begin":201,"end":209},"obj":"Species"},{"id":"645","span":{"begin":245,"end":255},"obj":"Species"},{"id":"646","span":{"begin":297,"end":305},"obj":"Species"},{"id":"647","span":{"begin":339,"end":349},"obj":"Species"},{"id":"648","span":{"begin":456,"end":464},"obj":"Species"},{"id":"649","span":{"begin":498,"end":508},"obj":"Species"},{"id":"650","span":{"begin":674,"end":684},"obj":"Species"},{"id":"651","span":{"begin":479,"end":487},"obj":"Species"},{"id":"652","span":{"begin":120,"end":140},"obj":"Disease"},{"id":"653","span":{"begin":148,"end":156},"obj":"Disease"}],"attributes":[{"id":"A639","pred":"tao:has_database_id","subj":"639","obj":"Gene:43740568"},{"id":"A640","pred":"tao:has_database_id","subj":"640","obj":"Gene:43740568"},{"id":"A641","pred":"tao:has_database_id","subj":"641","obj":"Tax:694009"},{"id":"A642","pred":"tao:has_database_id","subj":"642","obj":"Tax:1335626"},{"id":"A643","pred":"tao:has_database_id","subj":"643","obj":"Tax:694009"},{"id":"A644","pred":"tao:has_database_id","subj":"644","obj":"Tax:9606"},{"id":"A645","pred":"tao:has_database_id","subj":"645","obj":"Tax:2697049"},{"id":"A646","pred":"tao:has_database_id","subj":"646","obj":"Tax:694009"},{"id":"A647","pred":"tao:has_database_id","subj":"647","obj":"Tax:2697049"},{"id":"A648","pred":"tao:has_database_id","subj":"648","obj":"Tax:694009"},{"id":"A649","pred":"tao:has_database_id","subj":"649","obj":"Tax:2697049"},{"id":"A650","pred":"tao:has_database_id","subj":"650","obj":"Tax:2697049"},{"id":"A651","pred":"tao:has_database_id","subj":"651","obj":"Tax:1335626"},{"id":"A652","pred":"tao:has_database_id","subj":"652","obj":"MESH:C000657245"},{"id":"A653","pred":"tao:has_database_id","subj":"653","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Due to the high similarity of S proteins from SARS-CoV and MERS-CoV [73], their specific cross-nAbs were tested against SARS-CoV-2 infection in the COVID-19 outbreak. Serum Abs from recovered SARS-CoV patients could efficiently cross-neutralize SARS-CoV-2 but with lower efficiency as compared to SARS-CoV [92]. Cross-reactive Abs against SARS-CoV-2 S protein mostly target non-RBD regions [93]. Using simulation technique, the binding of five Abs against SARS-CoV, six Abs anti-MERS-CoV to RBD of SARS-CoV-2 was predicted with Rosetta antibody-antigen docking protocols. The amino acid position 445–449 (VGGNY) and 470–486 (TEIYQAGSTPCNGVEGF) were found to be conserved in SARS-CoV-2. Moreover, in addition to the amino acid positions 71–77 (GTNGTKR) in the NTD region of the S protein, aa 445–449 and 470–486 are potential for further development [94]."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T112","span":{"begin":32,"end":40},"obj":"Body_part"},{"id":"T113","span":{"begin":167,"end":172},"obj":"Body_part"},{"id":"T114","span":{"begin":352,"end":359},"obj":"Body_part"},{"id":"T115","span":{"begin":536,"end":544},"obj":"Body_part"},{"id":"T116","span":{"begin":576,"end":586},"obj":"Body_part"},{"id":"T117","span":{"begin":715,"end":725},"obj":"Body_part"},{"id":"T118","span":{"begin":779,"end":786},"obj":"Body_part"}],"attributes":[{"id":"A112","pred":"fma_id","subj":"T112","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A113","pred":"fma_id","subj":"T113","obj":"http://purl.org/sig/ont/fma/fma63083"},{"id":"A114","pred":"fma_id","subj":"T114","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A115","pred":"fma_id","subj":"T115","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A116","pred":"fma_id","subj":"T116","obj":"http://purl.org/sig/ont/fma/fma82739"},{"id":"A117","pred":"fma_id","subj":"T117","obj":"http://purl.org/sig/ont/fma/fma82739"},{"id":"A118","pred":"fma_id","subj":"T118","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"Due to the high similarity of S proteins from SARS-CoV and MERS-CoV [73], their specific cross-nAbs were tested against SARS-CoV-2 infection in the COVID-19 outbreak. Serum Abs from recovered SARS-CoV patients could efficiently cross-neutralize SARS-CoV-2 but with lower efficiency as compared to SARS-CoV [92]. Cross-reactive Abs against SARS-CoV-2 S protein mostly target non-RBD regions [93]. Using simulation technique, the binding of five Abs against SARS-CoV, six Abs anti-MERS-CoV to RBD of SARS-CoV-2 was predicted with Rosetta antibody-antigen docking protocols. The amino acid position 445–449 (VGGNY) and 470–486 (TEIYQAGSTPCNGVEGF) were found to be conserved in SARS-CoV-2. Moreover, in addition to the amino acid positions 71–77 (GTNGTKR) in the NTD region of the S protein, aa 445–449 and 470–486 are potential for further development [94]."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T4","span":{"begin":167,"end":172},"obj":"Body_part"}],"attributes":[{"id":"A4","pred":"uberon_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"}],"text":"Due to the high similarity of S proteins from SARS-CoV and MERS-CoV [73], their specific cross-nAbs were tested against SARS-CoV-2 infection in the COVID-19 outbreak. Serum Abs from recovered SARS-CoV patients could efficiently cross-neutralize SARS-CoV-2 but with lower efficiency as compared to SARS-CoV [92]. Cross-reactive Abs against SARS-CoV-2 S protein mostly target non-RBD regions [93]. Using simulation technique, the binding of five Abs against SARS-CoV, six Abs anti-MERS-CoV to RBD of SARS-CoV-2 was predicted with Rosetta antibody-antigen docking protocols. The amino acid position 445–449 (VGGNY) and 470–486 (TEIYQAGSTPCNGVEGF) were found to be conserved in SARS-CoV-2. Moreover, in addition to the amino acid positions 71–77 (GTNGTKR) in the NTD region of the S protein, aa 445–449 and 470–486 are potential for further development [94]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T102","span":{"begin":46,"end":54},"obj":"Disease"},{"id":"T103","span":{"begin":120,"end":128},"obj":"Disease"},{"id":"T104","span":{"begin":131,"end":140},"obj":"Disease"},{"id":"T105","span":{"begin":148,"end":156},"obj":"Disease"},{"id":"T106","span":{"begin":192,"end":200},"obj":"Disease"},{"id":"T107","span":{"begin":245,"end":253},"obj":"Disease"},{"id":"T108","span":{"begin":297,"end":305},"obj":"Disease"},{"id":"T109","span":{"begin":339,"end":347},"obj":"Disease"},{"id":"T110","span":{"begin":456,"end":464},"obj":"Disease"},{"id":"T111","span":{"begin":498,"end":506},"obj":"Disease"},{"id":"T112","span":{"begin":674,"end":682},"obj":"Disease"},{"id":"T113","span":{"begin":759,"end":762},"obj":"Disease"}],"attributes":[{"id":"A102","pred":"mondo_id","subj":"T102","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A103","pred":"mondo_id","subj":"T103","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A104","pred":"mondo_id","subj":"T104","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A105","pred":"mondo_id","subj":"T105","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A106","pred":"mondo_id","subj":"T106","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A107","pred":"mondo_id","subj":"T107","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A108","pred":"mondo_id","subj":"T108","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A109","pred":"mondo_id","subj":"T109","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A110","pred":"mondo_id","subj":"T110","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A111","pred":"mondo_id","subj":"T111","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A112","pred":"mondo_id","subj":"T112","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A113","pred":"mondo_id","subj":"T113","obj":"http://purl.obolibrary.org/obo/MONDO_0008449"},{"id":"A114","pred":"mondo_id","subj":"T113","obj":"http://purl.obolibrary.org/obo/MONDO_0018075"}],"text":"Due to the high similarity of S proteins from SARS-CoV and MERS-CoV [73], their specific cross-nAbs were tested against SARS-CoV-2 infection in the COVID-19 outbreak. Serum Abs from recovered SARS-CoV patients could efficiently cross-neutralize SARS-CoV-2 but with lower efficiency as compared to SARS-CoV [92]. Cross-reactive Abs against SARS-CoV-2 S protein mostly target non-RBD regions [93]. Using simulation technique, the binding of five Abs against SARS-CoV, six Abs anti-MERS-CoV to RBD of SARS-CoV-2 was predicted with Rosetta antibody-antigen docking protocols. The amino acid position 445–449 (VGGNY) and 470–486 (TEIYQAGSTPCNGVEGF) were found to be conserved in SARS-CoV-2. Moreover, in addition to the amino acid positions 71–77 (GTNGTKR) in the NTD region of the S protein, aa 445–449 and 470–486 are potential for further development [94]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T321","span":{"begin":105,"end":111},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T322","span":{"begin":736,"end":738},"obj":"http://purl.obolibrary.org/obo/CLO_0054055"},{"id":"T323","span":{"begin":788,"end":790},"obj":"http://purl.obolibrary.org/obo/CLO_0001627"},{"id":"T324","span":{"begin":850,"end":852},"obj":"http://purl.obolibrary.org/obo/CLO_0001527"}],"text":"Due to the high similarity of S proteins from SARS-CoV and MERS-CoV [73], their specific cross-nAbs were tested against SARS-CoV-2 infection in the COVID-19 outbreak. Serum Abs from recovered SARS-CoV patients could efficiently cross-neutralize SARS-CoV-2 but with lower efficiency as compared to SARS-CoV [92]. Cross-reactive Abs against SARS-CoV-2 S protein mostly target non-RBD regions [93]. Using simulation technique, the binding of five Abs against SARS-CoV, six Abs anti-MERS-CoV to RBD of SARS-CoV-2 was predicted with Rosetta antibody-antigen docking protocols. The amino acid position 445–449 (VGGNY) and 470–486 (TEIYQAGSTPCNGVEGF) were found to be conserved in SARS-CoV-2. Moreover, in addition to the amino acid positions 71–77 (GTNGTKR) in the NTD region of the S protein, aa 445–449 and 470–486 are potential for further development [94]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T143","span":{"begin":32,"end":40},"obj":"Chemical"},{"id":"T144","span":{"begin":352,"end":359},"obj":"Chemical"},{"id":"T145","span":{"begin":545,"end":552},"obj":"Chemical"},{"id":"T146","span":{"begin":576,"end":586},"obj":"Chemical"},{"id":"T147","span":{"begin":576,"end":581},"obj":"Chemical"},{"id":"T148","span":{"begin":582,"end":586},"obj":"Chemical"},{"id":"T149","span":{"begin":715,"end":725},"obj":"Chemical"},{"id":"T150","span":{"begin":715,"end":720},"obj":"Chemical"},{"id":"T151","span":{"begin":721,"end":725},"obj":"Chemical"},{"id":"T152","span":{"begin":779,"end":786},"obj":"Chemical"}],"attributes":[{"id":"A143","pred":"chebi_id","subj":"T143","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A144","pred":"chebi_id","subj":"T144","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A145","pred":"chebi_id","subj":"T145","obj":"http://purl.obolibrary.org/obo/CHEBI_59132"},{"id":"A146","pred":"chebi_id","subj":"T146","obj":"http://purl.obolibrary.org/obo/CHEBI_33709"},{"id":"A147","pred":"chebi_id","subj":"T147","obj":"http://purl.obolibrary.org/obo/CHEBI_46882"},{"id":"A148","pred":"chebi_id","subj":"T148","obj":"http://purl.obolibrary.org/obo/CHEBI_37527"},{"id":"A149","pred":"chebi_id","subj":"T149","obj":"http://purl.obolibrary.org/obo/CHEBI_33709"},{"id":"A150","pred":"chebi_id","subj":"T150","obj":"http://purl.obolibrary.org/obo/CHEBI_46882"},{"id":"A151","pred":"chebi_id","subj":"T151","obj":"http://purl.obolibrary.org/obo/CHEBI_37527"},{"id":"A152","pred":"chebi_id","subj":"T152","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"Due to the high similarity of S proteins from SARS-CoV and MERS-CoV [73], their specific cross-nAbs were tested against SARS-CoV-2 infection in the COVID-19 outbreak. Serum Abs from recovered SARS-CoV patients could efficiently cross-neutralize SARS-CoV-2 but with lower efficiency as compared to SARS-CoV [92]. Cross-reactive Abs against SARS-CoV-2 S protein mostly target non-RBD regions [93]. Using simulation technique, the binding of five Abs against SARS-CoV, six Abs anti-MERS-CoV to RBD of SARS-CoV-2 was predicted with Rosetta antibody-antigen docking protocols. The amino acid position 445–449 (VGGNY) and 470–486 (TEIYQAGSTPCNGVEGF) were found to be conserved in SARS-CoV-2. Moreover, in addition to the amino acid positions 71–77 (GTNGTKR) in the NTD region of the S protein, aa 445–449 and 470–486 are potential for further development [94]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T202","span":{"begin":0,"end":166},"obj":"Sentence"},{"id":"T203","span":{"begin":167,"end":311},"obj":"Sentence"},{"id":"T204","span":{"begin":312,"end":395},"obj":"Sentence"},{"id":"T205","span":{"begin":396,"end":571},"obj":"Sentence"},{"id":"T206","span":{"begin":572,"end":685},"obj":"Sentence"},{"id":"T207","span":{"begin":686,"end":854},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Due to the high similarity of S proteins from SARS-CoV and MERS-CoV [73], their specific cross-nAbs were tested against SARS-CoV-2 infection in the COVID-19 outbreak. Serum Abs from recovered SARS-CoV patients could efficiently cross-neutralize SARS-CoV-2 but with lower efficiency as compared to SARS-CoV [92]. Cross-reactive Abs against SARS-CoV-2 S protein mostly target non-RBD regions [93]. Using simulation technique, the binding of five Abs against SARS-CoV, six Abs anti-MERS-CoV to RBD of SARS-CoV-2 was predicted with Rosetta antibody-antigen docking protocols. The amino acid position 445–449 (VGGNY) and 470–486 (TEIYQAGSTPCNGVEGF) were found to be conserved in SARS-CoV-2. Moreover, in addition to the amino acid positions 71–77 (GTNGTKR) in the NTD region of the S protein, aa 445–449 and 470–486 are potential for further development [94]."}

{"project":"2_test","denotations":[{"id":"32450171-32015507-66454511","span":{"begin":69,"end":71},"obj":"32015507"}],"text":"Due to the high similarity of S proteins from SARS-CoV and MERS-CoV [73], their specific cross-nAbs were tested against SARS-CoV-2 infection in the COVID-19 outbreak. Serum Abs from recovered SARS-CoV patients could efficiently cross-neutralize SARS-CoV-2 but with lower efficiency as compared to SARS-CoV [92]. Cross-reactive Abs against SARS-CoV-2 S protein mostly target non-RBD regions [93]. Using simulation technique, the binding of five Abs against SARS-CoV, six Abs anti-MERS-CoV to RBD of SARS-CoV-2 was predicted with Rosetta antibody-antigen docking protocols. The amino acid position 445–449 (VGGNY) and 470–486 (TEIYQAGSTPCNGVEGF) were found to be conserved in SARS-CoV-2. Moreover, in addition to the amino acid positions 71–77 (GTNGTKR) in the NTD region of the S protein, aa 445–449 and 470–486 are potential for further development [94]."}